Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN362331 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Epidermal Growth Factor Receptor (EGFR) (pTyr1110) antibody
- Antibody type
- Polyclonal
- Antigen
- Peptide sequence around phosphorylation site of pTyr1110 (P-V-Y (p) -H-N) derived from Human EGFR. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates.
- Description
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- pTyr1110
- Isotype
- IgG
- Vial size
- 50 μL
- Concentration
- 1 mg/mL
- Storage
- Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.
Submitted references Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade.
Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Jul 1;12(13):4103-11
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Jul 1;12(13):4103-11
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Apr;9(4):1274-83
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Apr;9(4):1274-83
Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade.
Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M, Cary LA, Moolenaar WH, Schlessinger J
The Journal of biological chemistry 2001 Jun 8;276(23):20130-5
The Journal of biological chemistry 2001 Jun 8;276(23):20130-5
No comments: Submit comment
No validations: Submit validation data